CLEAR CELL RENAL CELL CARCINOMA

This study tests whether adding tivozanib to the standard immunotherapy pembrolizumab can better prevent high-risk kidney cancer from returning after surgery. About 1,040 adults with clear cell renal cell carcinoma at intermediate-high or high risk will be randomly assigned to ge…

This study tests a new medicine, PF-08634404, for adults with advanced kidney cancer that has spread. The goal is to see if the drug, given alone or with other cancer treatments, can shrink tumors and is safe. Participants must not have had prior treatment for their advanced canc…

This study tests whether giving belzutifan alone, pembrolizumab alone, or both together before kidney surgery can help control advanced clear cell kidney cancer. About 10 people with high-risk or early-spread kidney cancer will receive one of these treatments before having part o…

This study tests whether adding a second drug (fianlimab) to the immunotherapy cemiplimab can help keep kidney cancer from growing after radiation treatment. About 72 adults with kidney cancer that has spread to a few other spots will receive either cemiplimab alone or both drugs…

This study tests a new drug (zanzalintinib) alone or with an immunotherapy (nivolumab) in 70 adults with advanced kidney cancer that worsened after standard initial treatment. The goal is to see if the combination shrinks tumors better than the drug alone. Participants will take …

This study tests whether adding the experimental drug SLC-3010 to the standard drug axitinib works better than axitinib alone for people with advanced clear cell kidney cancer that has worsened after first treatment. About 78 adults will be randomly assigned to one of the two gro…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This early-stage study tests a new drug called NEO-811 in people with advanced clear cell kidney cancer that cannot be removed by surgery. About 30 participants who have tried other treatments or cannot take them will receive the drug to see if it is safe and what dose works best…

This study tests a combination of three drugs—177Lu girentuximab, cabozantinib, and nivolumab—in people with advanced clear cell kidney cancer who have not had treatment before. The goal is to see if this mix can help control the cancer. About 100 adults will take part, and the s…

This early-phase study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the dru…

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…

This early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer dru…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can shrink kidney tumors enough to allow partial kidney removal in patients who otherwise would need full kidney removal. Ab…

This study is developing a new, non-invasive urine test to detect clear cell kidney cancer. Instead of a painful and expensive biopsy, doctors would look for tiny particles called exosomes in the urine that are released by cancer cells. The goal is to catch the cancer earlier and…

This study tests a special PET/CT scan that uses a radioactive tracer called [18F]PT2385 to see kidney cancer in more detail. It is not a treatment—it is an exploratory imaging study. About 35 adults with kidney cancer will get the scan, and some will also have a biopsy to compar…